This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Acadia (ACAD) Begins Study on ACP-101 for Hyperphagia in PWS
by Zacks Equity Research
Acadia (ACAD) begins late-stage development of carbetocin nasal spray for the treatment of hyperphagia in Prader-Willi syndrome.
Seagen's (SGEN) Combo Drug Expanded-Use sBLA Gets Priority Tag
by Zacks Equity Research
Seagen (SGEN) and Astellas Pharma announce that the FDA has accepted the label expansion-seeking application for the Padcev/Keytruda combo under priority review to treat first-line bladder cancer.
BioVie (BIVI) Falls 61% Despite Upbeat Alzheimer's Study Data
by Zacks Equity Research
BioVie (BIVI) stock plunges 61% in spite of positive phase III Alzheimer's Disease study results due to significant study conduct violations and protocol deviations reported by the company.
Acadia (ACAD) Begins Alzheimer's Disease Psychosis Study (Revised)
by Zacks Equity Research
Acadia (ACAD) initiates a phase II study on ACP-204 in the treatment of Alzheimer's disease psychosis, the first among the three studies planned in the phase II/III clinical program of the candidate.
Acadia (ACAD) Begins Alzheimer's Disease Psychosis Study
by Zacks Equity Research
Acadia (ACAD) initiates a phase II study on ACP-204 in the treatment of Alzheimer's disease psychosis, the first among the three studies planned in the phase II/III clinical program of the candidate.
Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Adma Biologics (ADMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Is Aurinia Pharmaceuticals (AUPH) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Aurinia Pharmaceuticals (AUPH) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of 0% and 2.07%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Adma Biologics (ADMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Immatics (IMTX) Moves 23.2% Higher: Will This Strength Last?
by Zacks Equity Research
Immatics (IMTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
Adma Biologics (ADMA) closed the most recent trading day at $3.45, moving -1.99% from the previous trading session.
Adma Biologics (ADMA) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
Adma Biologics (ADMA) closed at $3.31 in the latest trading session, marking a +0.91% move from the prior day.
Adma Biologics (ADMA) Stock Moves -0.94%: What You Should Know
by Zacks Equity Research
Adma Biologics (ADMA) reachead $3.17 at the closing of the latest trading day, reflecting a -0.94% change compared to its last close.
Adma Biologics (ADMA) Rises As Market Takes a Dip: Key Facts
by Zacks Equity Research
In the most recent trading session, Adma Biologics (ADMA) closed at $3.44, indicating a +1.78% shift from the previous trading day.
Adma Biologics (ADMA) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
In the closing of the recent trading day, Adma Biologics (ADMA) stood at $3.34, denoting a -0.3% change from the preceding trading day.
Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Adma Biologics (ADMA). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Adma Biologics (ADMA) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Adma Biologics (ADMA) closed the most recent trading day at $3.59, moving +1.13% from the previous trading session.
Adma Biologics (ADMA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Adma Biologics (ADMA) closed at $3.56, marking a +0.28% move from the previous day.
Adma Biologics (ADMA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Adma Biologics (ADMA) closed at $3.78 in the latest trading session, marking a -0.26% move from the prior day.
Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Adma Biologics (ADMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Atreca (BCEL) Suspends Lead Drug Evaluation, Stock Falls 37%
by Zacks Equity Research
Atreca (BCEL) suspends the development of only pipeline candidate, ATRC-101, in clinical evaluation, as part of its business restructuring efforts and cuts headcount by 40%. The stock falls 37%.
Catalyst (CPRX) Q2 Earnings & Sales Top, 2023 Outlook Raised
by Zacks Equity Research
Catalyst (CPRX) reports better-than-expected second-quarter 2023 results. Management raises full-year 2023 guidance.
Novo Nordisk (NVO) Q2 Earnings and Sales Miss, 2023 View Up
by Zacks Equity Research
Novo Nordisk (NVO) reports weaker-than-expected second-quarter 2023 results, missing both earnings and sales estimates. Management, however, raises 2023 guidance.
Is ADMA Biologics (ADMA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Adma Biologics (ADMA) and Align Technology (ALGN) have performed compared to their sector so far this year.
Adma Biologics (ADMA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Adma Biologics (ADMA) delivered earnings and revenue surprises of 0% and 8.43%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?